Mallinckrodt plc Ordinary Share (NYSE:MNK):
Mallinckrodt Pharmaceuticals Donates Drug Deactivation Pouches to Enable Safe Disposal of Prescription Drugs in Indiana.
The company is down by -2.63% since yesterday’s close of $63.04.
Company shares last traded at $61.38 slightly below $69.45, the 50 day moving average and which is marginally lower than the 200 day moving average of $66.80. The 50 day moving average was down by -11.62% whereas the 200 day average was down by -8.12%.
The company currently has a P/E ratio of 11.57 and the market cap is 6.61B. In the last earnings report the EPS was $5.30 and is expected to be $7.64 for the current year with 107,713,000 shares now outstanding. Next quarter’s EPS is forecasted to be $1.90 with next year’s EPS anticipated to be $8.09.
Several ratings firms have released opinions on the stock of late. August 31 investment analysts at Deutsche Bank kept the company rating at “Buy” but lowered the price target to $84.00 from $87.00. On August 25 Barclays kept the stock rating at “Overweight” but raised the price expectation from $80.00 to $112.00.
On August 24 Piper Jaffray maintained a stock rating of “Overweight” and raised the price target to $112.00 from $102.00. Stifel Nicolaus started coverage by announcing an initial rating of “Buy”.
On June 29 analysts at BMO Capital started covering MNK giving it an initial rating of “Outperform”. May 4 investment analysts at JP Morgan left the company rating at “Neutral” but moved down the price target to $85.00 from $120.00.